Our purpose
To manufacture biotech drugs faster and more efficiently so that everyone, everywhere, can get them

Our philosophy
Taking a viral vector or RNA-based therapy from pre-clinical development to the first GMP batch for clinical trials can be a complex journey. One of the greatest hurdles is the limited access to both specialized process development expertise and GMP manufacturing facilities that can quickly and cost-effectively deliver the high-quality product needed for clinical studies and beyond.
Exothera stands as end-to-end CDMO partner, ready to help you navigate these challenges. We bring the expertise and flexibility to efficiently complete process development and manufacture the precise quantity of therapy required to move your clinical trials forward, secure additional funding, and accelerate your therapy’s journey to market.
OUR HIGHLIGHTS
Within 5 years, we achieved many milestones, testimony of our continuous strive for innovation in the way we offer our services.
2020
Incorporation of Exothera as a specialized viral vector CDMO
2022
Belgian FAMHP authority accreditation
Jan 2023
Lauch of the RNA business unit
Mid 2023
First viral vector GMP project
April 2024
Finalized IOQ of Ntensify RNA platform
May 2024
First RNA GMP project
Q3 2024